Tuesday January 5, 11:39 am Eastern Time
Company Press Release
Biopool International Enters Into New
Supply Agreement with i-STAT Corp.
VENTURA, Calif.--(BW HealthWire)--Jan. 5, 1999--Biopool International Inc. (Nasdaq:BIPL - news)
Tuesday announced that the Company has entered into a Supply Agreement with i-STAT Corp.
(Nasdaq:STAT - news) to provide specialized control products designed for use on the hemostasis
cartridges and instruments currently under development at i-STAT.
Michael D. Bick, Ph.D., chairman and chief executive officer of Biopool, stated: ''Biopool developed
these customized plasma control products to support the i-STAT test system during 1998 and, indeed,
received FDA clearance on the products in June of last year. Since that time, we have delivered product
to i-STAT to support their ongoing clinical evaluations. Full commercialization of the test system is
expected to begin late in 1999.''
Dr. Bick added, ''The initial term of the Supply Agreement is three years, and we expect to add
additional products to the agreement during that term.''
i-STAT develops, manufactures and markets diagnostic products for blood analysis that provide health
care professionals critical diagnostic information accurately and immediately at the point of patient care.
Through the use of advanced semiconductor manufacturing technology, established principles of
electrochemistry and state-of-the-art computer electronics and software, i-STAT developed the world's
first hand-held automated blood analyzer capable of performing a panel of commonly ordered blood tests
on two or three drops of blood in just two minutes at the patient's side.
Founded in 1987, Biopool International develops, manufactures, and markets a full range of test kits to
assess and diagnose disorders of blood coagulation, thrombotic risk factors, fibrinolysis, platelet function,
and the vascular system; specialty chemistry controls used to monitor and measure the presence of drugs
of abuse; and blood group serology products used to screen for antibodies and group and type whole
blood.
The Company's product line of over 150 FDA-approved products is sold to hospitals, blood bank
facilities, and clinical and reference laboratories on a worldwide basis by the Company's own sales
representatives, as well as through an extensive network of distributors. To learn more about Biopool,
visit the Company's web site at biopool.com.
NOTE: This news release contains forward-looking statements regarding the expected commercialization
of a new test system, which are based upon current expectations that involve a number of risks and
uncertainties including, but not limited to, technological innovations of competitors, changes in health care
regulations, litigation claims, foreign currency fluctuation, product acceptance or changes in government
regulation of the Company's products, as well as other factors discussed in the Company's last Report on
Form 10-K-SB under ''Risk Factors.''
Contact:
Biopool International Inc., Ventura
Michael D. Bick, Ph.D., or Carol Hill, 805/654-0643
More Quotes
and News:
Biopool International Inc (Nasdaq:BIPL - news)
I-Stat Corp (Nasdaq:STAT - news)
Related News Categories: biotech, medical/pharmaceutical |
